Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Mesenchymal Stem Cells | 26 | 2015 | 161 | 4.700 |
Why?
|
Ovarian Neoplasms | 8 | 2013 | 87 | 1.990 |
Why?
|
Mesenchymal Stem Cell Transplantation | 9 | 2012 | 75 | 1.610 |
Why?
|
Stromal Cells | 5 | 2016 | 70 | 1.450 |
Why?
|
Neoplasms | 10 | 2018 | 610 | 1.410 |
Why?
|
Cell Movement | 9 | 2016 | 161 | 1.210 |
Why?
|
Bone Marrow Cells | 8 | 2013 | 114 | 1.130 |
Why?
|
Fibroblasts | 6 | 2013 | 103 | 1.090 |
Why?
|
Mice | 38 | 2019 | 2368 | 1.080 |
Why?
|
Breast Neoplasms | 10 | 2019 | 666 | 0.990 |
Why?
|
Animals | 51 | 2019 | 7297 | 0.980 |
Why?
|
Cell Line, Tumor | 25 | 2019 | 680 | 0.960 |
Why?
|
Cell Differentiation | 10 | 2016 | 436 | 0.860 |
Why?
|
Bone Marrow Transplantation | 3 | 2013 | 65 | 0.820 |
Why?
|
Mammary Neoplasms, Animal | 2 | 2013 | 10 | 0.790 |
Why?
|
Interferon-beta | 7 | 2013 | 23 | 0.780 |
Why?
|
Adipocytes | 5 | 2016 | 79 | 0.690 |
Why?
|
Inflammation | 3 | 2012 | 507 | 0.670 |
Why?
|
Glioma | 6 | 2016 | 133 | 0.660 |
Why?
|
Adenoviridae | 10 | 2013 | 61 | 0.630 |
Why?
|
Flow Cytometry | 9 | 2014 | 171 | 0.630 |
Why?
|
Green Fluorescent Proteins | 4 | 2013 | 71 | 0.620 |
Why?
|
Osteoblasts | 3 | 2019 | 46 | 0.580 |
Why?
|
Microscopy, Fluorescence | 2 | 2013 | 81 | 0.560 |
Why?
|
Adipose Tissue | 4 | 2013 | 327 | 0.540 |
Why?
|
Drug Resistance, Neoplasm | 6 | 2017 | 89 | 0.530 |
Why?
|
Genetic Vectors | 9 | 2012 | 118 | 0.530 |
Why?
|
Humans | 52 | 2019 | 29093 | 0.500 |
Why?
|
Cell Proliferation | 11 | 2019 | 573 | 0.480 |
Why?
|
Leukemia | 3 | 2010 | 36 | 0.460 |
Why?
|
Gene Transfer Techniques | 4 | 2011 | 69 | 0.450 |
Why?
|
Cell Lineage | 4 | 2016 | 67 | 0.430 |
Why?
|
Apoptosis | 10 | 2015 | 337 | 0.420 |
Why?
|
Brain Neoplasms | 7 | 2016 | 587 | 0.410 |
Why?
|
Xenograft Model Antitumor Assays | 12 | 2019 | 113 | 0.410 |
Why?
|
Mesoderm | 2 | 2009 | 14 | 0.410 |
Why?
|
Cell Migration Assays | 1 | 2011 | 2 | 0.400 |
Why?
|
Nanoparticles | 3 | 2016 | 47 | 0.400 |
Why?
|
Pancreatic Neoplasms | 2 | 2010 | 131 | 0.400 |
Why?
|
Female | 24 | 2019 | 18164 | 0.390 |
Why?
|
Cell Separation | 7 | 2016 | 86 | 0.390 |
Why?
|
Neoplastic Stem Cells | 4 | 2013 | 90 | 0.370 |
Why?
|
T-Lymphocytes | 2 | 2009 | 114 | 0.370 |
Why?
|
Mice, Inbred C57BL | 7 | 2016 | 711 | 0.370 |
Why?
|
Chemotaxis | 1 | 2009 | 23 | 0.360 |
Why?
|
Phenotype | 5 | 2017 | 629 | 0.360 |
Why?
|
Transduction, Genetic | 10 | 2012 | 42 | 0.350 |
Why?
|
Mice, Nude | 13 | 2019 | 276 | 0.340 |
Why?
|
Hematopoietic Stem Cells | 5 | 2012 | 95 | 0.330 |
Why?
|
Graft Survival | 1 | 2009 | 228 | 0.320 |
Why?
|
Neoplasm Transplantation | 7 | 2013 | 76 | 0.320 |
Why?
|
Disease Models, Animal | 5 | 2016 | 980 | 0.320 |
Why?
|
Hyaluronic Acid | 3 | 2016 | 45 | 0.310 |
Why?
|
Luminescent Proteins | 3 | 2013 | 24 | 0.310 |
Why?
|
Graft vs Host Disease | 1 | 2007 | 18 | 0.300 |
Why?
|
Culture Media, Conditioned | 8 | 2019 | 52 | 0.300 |
Why?
|
Cells, Cultured | 9 | 2013 | 799 | 0.300 |
Why?
|
Immunohistochemistry | 7 | 2014 | 519 | 0.290 |
Why?
|
Infrared Rays | 2 | 2016 | 18 | 0.290 |
Why?
|
Mice, Transgenic | 4 | 2016 | 249 | 0.290 |
Why?
|
Luminescent Measurements | 3 | 2018 | 16 | 0.280 |
Why?
|
Stem Cells | 2 | 2007 | 292 | 0.270 |
Why?
|
Mice, SCID | 9 | 2012 | 71 | 0.270 |
Why?
|
Cord Blood Stem Cell Transplantation | 3 | 2010 | 8 | 0.270 |
Why?
|
Glioblastoma | 3 | 2016 | 143 | 0.270 |
Why?
|
Surgery, Computer-Assisted | 2 | 2016 | 56 | 0.260 |
Why?
|
Signal Transduction | 4 | 2018 | 666 | 0.250 |
Why?
|
Oligopeptides | 4 | 2010 | 51 | 0.250 |
Why?
|
Fluorescent Dyes | 2 | 2015 | 45 | 0.240 |
Why?
|
Postural Balance | 1 | 2016 | 160 | 0.240 |
Why?
|
Models, Biological | 3 | 2017 | 373 | 0.240 |
Why?
|
Neoplasm Metastasis | 5 | 2013 | 199 | 0.230 |
Why?
|
Pesticides | 1 | 2016 | 189 | 0.230 |
Why?
|
Interleukin-6 | 3 | 2015 | 225 | 0.230 |
Why?
|
Cell Division | 5 | 2012 | 97 | 0.230 |
Why?
|
Thymidine Kinase | 3 | 2012 | 5 | 0.230 |
Why?
|
Occupational Exposure | 1 | 2016 | 224 | 0.230 |
Why?
|
Omentum | 2 | 2013 | 26 | 0.220 |
Why?
|
Emigrants and Immigrants | 1 | 2016 | 235 | 0.220 |
Why?
|
Transients and Migrants | 1 | 2016 | 281 | 0.220 |
Why?
|
Neoplasm Recurrence, Local | 2 | 2016 | 337 | 0.220 |
Why?
|
Cell Transformation, Neoplastic | 4 | 2013 | 57 | 0.210 |
Why?
|
Gene Expression Regulation, Neoplastic | 4 | 2016 | 249 | 0.210 |
Why?
|
Ganciclovir | 3 | 2012 | 14 | 0.210 |
Why?
|
Antineoplastic Agents | 3 | 2014 | 546 | 0.200 |
Why?
|
Transgenes | 4 | 2010 | 45 | 0.200 |
Why?
|
Stem Cell Transplantation | 2 | 2016 | 203 | 0.190 |
Why?
|
Transplantation, Heterologous | 6 | 2012 | 121 | 0.190 |
Why?
|
Carcinoma | 2 | 2012 | 87 | 0.190 |
Why?
|
Cell Communication | 2 | 2019 | 30 | 0.190 |
Why?
|
Lung Neoplasms | 3 | 2010 | 384 | 0.180 |
Why?
|
Endothelial Cells | 3 | 2016 | 179 | 0.180 |
Why?
|
Hispanic Americans | 1 | 2016 | 904 | 0.180 |
Why?
|
Monocytes | 3 | 2016 | 119 | 0.170 |
Why?
|
Receptor, TIE-2 | 2 | 2016 | 5 | 0.170 |
Why?
|
Neoplasm Proteins | 5 | 2012 | 141 | 0.170 |
Why?
|
STAT3 Transcription Factor | 3 | 2015 | 22 | 0.170 |
Why?
|
Extracellular Matrix | 2 | 2013 | 226 | 0.170 |
Why?
|
Breast | 3 | 2019 | 53 | 0.170 |
Why?
|
Blotting, Western | 4 | 2013 | 281 | 0.160 |
Why?
|
Feedback, Physiological | 1 | 2018 | 10 | 0.160 |
Why?
|
Receptors, Adrenergic, beta-3 | 1 | 2018 | 5 | 0.160 |
Why?
|
TNF-Related Apoptosis-Inducing Ligand | 2 | 2016 | 10 | 0.160 |
Why?
|
Oncolytic Virotherapy | 2 | 2009 | 19 | 0.160 |
Why?
|
Brain-Derived Neurotrophic Factor | 1 | 2018 | 36 | 0.160 |
Why?
|
Contrast Media | 2 | 2016 | 123 | 0.160 |
Why?
|
Phantoms, Imaging | 1 | 2018 | 56 | 0.160 |
Why?
|
Norepinephrine | 1 | 2018 | 73 | 0.160 |
Why?
|
Mucous Membrane | 1 | 2017 | 20 | 0.160 |
Why?
|
Bone Neoplasms | 1 | 2019 | 104 | 0.150 |
Why?
|
Radiopharmaceuticals | 1 | 2018 | 87 | 0.150 |
Why?
|
Bioengineering | 1 | 2017 | 67 | 0.150 |
Why?
|
Cell Line | 4 | 2012 | 449 | 0.150 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2013 | 248 | 0.150 |
Why?
|
Fluorescent Antibody Technique | 2 | 2014 | 82 | 0.150 |
Why?
|
Organoids | 1 | 2017 | 68 | 0.150 |
Why?
|
Pericytes | 1 | 2016 | 28 | 0.140 |
Why?
|
Male | 12 | 2016 | 17807 | 0.140 |
Why?
|
Fluorescence | 1 | 2016 | 21 | 0.140 |
Why?
|
Leukemia, Myeloid | 3 | 2010 | 24 | 0.140 |
Why?
|
Benzamides | 2 | 2014 | 54 | 0.140 |
Why?
|
Exosomes | 1 | 2016 | 38 | 0.140 |
Why?
|
Materials Testing | 1 | 2016 | 84 | 0.140 |
Why?
|
Transfection | 4 | 2010 | 192 | 0.140 |
Why?
|
Cytokine Receptor gp130 | 1 | 2015 | 1 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-bcl-2 | 2 | 2006 | 31 | 0.130 |
Why?
|
Immunoenzyme Techniques | 2 | 2013 | 46 | 0.130 |
Why?
|
Colorectal Neoplasms | 1 | 2017 | 208 | 0.130 |
Why?
|
Indocyanine Green | 1 | 2015 | 13 | 0.130 |
Why?
|
Rhabdomyosarcoma, Alveolar | 1 | 2014 | 1 | 0.130 |
Why?
|
Pyridines | 1 | 2014 | 78 | 0.120 |
Why?
|
MicroRNAs | 1 | 2016 | 173 | 0.120 |
Why?
|
Cell Growth Processes | 2 | 2010 | 9 | 0.120 |
Why?
|
Fluorouracil | 2 | 2017 | 73 | 0.120 |
Why?
|
Chromatin Immunoprecipitation | 1 | 2013 | 21 | 0.120 |
Why?
|
Macrophages | 1 | 2015 | 188 | 0.120 |
Why?
|
Indoles | 1 | 2013 | 58 | 0.120 |
Why?
|
Leukemia, Lymphocytic, Chronic, B-Cell | 2 | 2003 | 17 | 0.120 |
Why?
|
Arabinofuranosyluracil | 2 | 2011 | 2 | 0.120 |
Why?
|
Herpesvirus 1, Human | 2 | 2011 | 5 | 0.110 |
Why?
|
Positron-Emission Tomography | 2 | 2011 | 172 | 0.110 |
Why?
|
Angiogenesis Inducing Agents | 2 | 2010 | 15 | 0.110 |
Why?
|
RNA, Messenger | 2 | 2013 | 514 | 0.110 |
Why?
|
Mice, Inbred BALB C | 2 | 2016 | 160 | 0.110 |
Why?
|
Genes, Transgenic, Suicide | 1 | 2012 | 1 | 0.110 |
Why?
|
Cell Culture Techniques | 2 | 2010 | 165 | 0.110 |
Why?
|
Transforming Growth Factor beta | 1 | 2013 | 66 | 0.110 |
Why?
|
Bone Marrow | 1 | 2013 | 60 | 0.110 |
Why?
|
Gangliosides | 1 | 2012 | 6 | 0.110 |
Why?
|
Hematopoiesis | 1 | 2012 | 34 | 0.110 |
Why?
|
Neoplasm Invasiveness | 2 | 2014 | 189 | 0.110 |
Why?
|
Homeodomain Proteins | 1 | 2012 | 50 | 0.110 |
Why?
|
Osteocytes | 1 | 2012 | 4 | 0.110 |
Why?
|
Muscle, Skeletal | 1 | 2016 | 494 | 0.110 |
Why?
|
Antigens, CD34 | 2 | 2009 | 54 | 0.100 |
Why?
|
Retroviridae | 2 | 2012 | 25 | 0.100 |
Why?
|
Endometrial Neoplasms | 1 | 2011 | 34 | 0.100 |
Why?
|
Regeneration | 1 | 2013 | 167 | 0.100 |
Why?
|
Chondrocytes | 1 | 2012 | 71 | 0.100 |
Why?
|
Fetal Blood | 2 | 2009 | 35 | 0.100 |
Why?
|
Membrane Glycoproteins | 2 | 2018 | 97 | 0.100 |
Why?
|
Amniotic Fluid | 1 | 2011 | 84 | 0.100 |
Why?
|
Neuropilin-1 | 1 | 2010 | 11 | 0.100 |
Why?
|
Adenocarcinoma, Bronchiolo-Alveolar | 1 | 2010 | 3 | 0.100 |
Why?
|
Cell Survival | 5 | 2011 | 272 | 0.100 |
Why?
|
Immunomodulation | 1 | 2011 | 30 | 0.100 |
Why?
|
Umbilical Cord | 1 | 2010 | 8 | 0.100 |
Why?
|
Growth Inhibitors | 1 | 2010 | 7 | 0.100 |
Why?
|
Antimetabolites, Antineoplastic | 2 | 2008 | 48 | 0.100 |
Why?
|
Genetic Engineering | 2 | 2007 | 19 | 0.100 |
Why?
|
Cerebral Arteries | 1 | 2010 | 18 | 0.100 |
Why?
|
Cadherins | 1 | 2010 | 24 | 0.100 |
Why?
|
Lymphoma | 1 | 2010 | 36 | 0.090 |
Why?
|
Myocardium | 1 | 2011 | 170 | 0.090 |
Why?
|
Regenerative Medicine | 1 | 2013 | 187 | 0.090 |
Why?
|
Platelet-Derived Growth Factor | 1 | 2010 | 13 | 0.090 |
Why?
|
Immunosuppression | 1 | 2010 | 80 | 0.090 |
Why?
|
Disease Progression | 2 | 2009 | 572 | 0.090 |
Why?
|
Tissue Scaffolds | 1 | 2013 | 386 | 0.090 |
Why?
|
Viscera | 1 | 2009 | 17 | 0.090 |
Why?
|
Coculture Techniques | 4 | 2016 | 74 | 0.090 |
Why?
|
Tumor Cells, Cultured | 5 | 2012 | 158 | 0.090 |
Why?
|
Adoptive Transfer | 1 | 2009 | 16 | 0.090 |
Why?
|
Tomography, X-Ray Computed | 2 | 2011 | 871 | 0.090 |
Why?
|
Antimicrobial Cationic Peptides | 1 | 2009 | 14 | 0.090 |
Why?
|
Multipotent Stem Cells | 1 | 2009 | 15 | 0.090 |
Why?
|
Kidney | 1 | 2013 | 485 | 0.090 |
Why?
|
Urinary Bladder Neoplasms | 1 | 2011 | 179 | 0.090 |
Why?
|
Peptide Library | 2 | 2010 | 6 | 0.080 |
Why?
|
Fetal Stem Cells | 1 | 2008 | 10 | 0.080 |
Why?
|
Inflammation Mediators | 1 | 2009 | 101 | 0.080 |
Why?
|
Vascular Endothelial Growth Factor A | 3 | 2014 | 103 | 0.080 |
Why?
|
Luciferases | 1 | 2007 | 27 | 0.080 |
Why?
|
Myocardial Infarction | 1 | 2011 | 412 | 0.080 |
Why?
|
Mice, Inbred AKR | 1 | 2007 | 4 | 0.080 |
Why?
|
Dose-Response Relationship, Immunologic | 1 | 2007 | 15 | 0.080 |
Why?
|
Injections, Subcutaneous | 1 | 2007 | 33 | 0.080 |
Why?
|
Injections, Intraperitoneal | 1 | 2007 | 41 | 0.080 |
Why?
|
Mice, Inbred NOD | 3 | 2012 | 25 | 0.080 |
Why?
|
Transplantation, Homologous | 1 | 2007 | 113 | 0.070 |
Why?
|
Nitrophenols | 1 | 2006 | 3 | 0.070 |
Why?
|
Biphenyl Compounds | 1 | 2006 | 19 | 0.070 |
Why?
|
Wounds and Injuries | 1 | 2009 | 250 | 0.070 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 3 | 2014 | 152 | 0.070 |
Why?
|
Capsid | 1 | 2006 | 9 | 0.070 |
Why?
|
Chromatography, Gel | 1 | 2006 | 6 | 0.070 |
Why?
|
Centrifugation, Density Gradient | 1 | 2006 | 11 | 0.070 |
Why?
|
Sulfonamides | 1 | 2006 | 65 | 0.070 |
Why?
|
raf Kinases | 1 | 2005 | 1 | 0.070 |
Why?
|
Cytokines | 1 | 2007 | 243 | 0.070 |
Why?
|
Stomach Neoplasms | 1 | 2006 | 85 | 0.070 |
Why?
|
Diagnostic Imaging | 1 | 2006 | 88 | 0.070 |
Why?
|
Antigens | 2 | 2016 | 31 | 0.070 |
Why?
|
Angiogenesis Inhibitors | 2 | 2016 | 34 | 0.070 |
Why?
|
Survival Rate | 1 | 2007 | 795 | 0.060 |
Why?
|
Leukemia, Myeloid, Acute | 1 | 2006 | 173 | 0.060 |
Why?
|
Genes, Reporter | 3 | 2011 | 37 | 0.060 |
Why?
|
Telomerase | 1 | 2004 | 21 | 0.060 |
Why?
|
Epithelial Cells | 2 | 2017 | 138 | 0.060 |
Why?
|
Neovascularization, Physiologic | 2 | 2016 | 106 | 0.060 |
Why?
|
Oncogene Proteins, Fusion | 1 | 2003 | 16 | 0.060 |
Why?
|
Leukemia, Promyelocytic, Acute | 1 | 2003 | 21 | 0.060 |
Why?
|
Case-Control Studies | 1 | 2016 | 859 | 0.060 |
Why?
|
Receptors, Cell Surface | 1 | 2003 | 72 | 0.060 |
Why?
|
Bystander Effect | 1 | 2003 | 6 | 0.060 |
Why?
|
Promoter Regions, Genetic | 1 | 2004 | 212 | 0.060 |
Why?
|
CD40 Ligand | 1 | 2003 | 13 | 0.060 |
Why?
|
Time Factors | 4 | 2011 | 2001 | 0.060 |
Why?
|
Brain | 1 | 2010 | 930 | 0.060 |
Why?
|
Melanoma | 1 | 2004 | 148 | 0.060 |
Why?
|
Tumor Necrosis Factor-alpha | 1 | 2004 | 200 | 0.060 |
Why?
|
Capsid Proteins | 1 | 2002 | 7 | 0.060 |
Why?
|
ATP-Binding Cassette Transporters | 1 | 2002 | 60 | 0.050 |
Why?
|
North Carolina | 1 | 2016 | 1423 | 0.050 |
Why?
|
Acute Disease | 3 | 2010 | 239 | 0.050 |
Why?
|
Macaca mulatta | 2 | 2012 | 322 | 0.040 |
Why?
|
RNA Interference | 2 | 2010 | 76 | 0.040 |
Why?
|
Bone Matrix | 1 | 2019 | 3 | 0.040 |
Why?
|
NIH 3T3 Cells | 1 | 2019 | 43 | 0.040 |
Why?
|
Antiviral Agents | 2 | 2012 | 100 | 0.040 |
Why?
|
Peritoneum | 2 | 2012 | 24 | 0.040 |
Why?
|
Cell Death | 2 | 2010 | 71 | 0.040 |
Why?
|
Receptor, trkB | 1 | 2018 | 2 | 0.040 |
Why?
|
Guanine Nucleotide Exchange Factors | 1 | 2018 | 12 | 0.040 |
Why?
|
Cyclic AMP | 1 | 2018 | 40 | 0.040 |
Why?
|
Recombinant Proteins | 2 | 2011 | 248 | 0.040 |
Why?
|
U937 Cells | 2 | 2010 | 8 | 0.040 |
Why?
|
Swine | 2 | 2011 | 201 | 0.040 |
Why?
|
Peripheral Nerves | 1 | 2018 | 58 | 0.040 |
Why?
|
Rabbits | 1 | 2017 | 185 | 0.040 |
Why?
|
Amino Acid Sequence | 2 | 2010 | 280 | 0.040 |
Why?
|
Molecular Sequence Data | 2 | 2010 | 350 | 0.040 |
Why?
|
Proteoglycans | 1 | 2016 | 29 | 0.040 |
Why?
|
Angiopoietin-2 | 1 | 2016 | 3 | 0.040 |
Why?
|
Collagen | 1 | 2017 | 217 | 0.040 |
Why?
|
Chemotaxis, Leukocyte | 1 | 2016 | 18 | 0.040 |
Why?
|
Gene Expression | 2 | 2010 | 332 | 0.040 |
Why?
|
Phosphorylation | 2 | 2008 | 225 | 0.030 |
Why?
|
Adult | 2 | 2016 | 8420 | 0.030 |
Why?
|
Aged | 2 | 2016 | 9487 | 0.030 |
Why?
|
Ligands | 2 | 2006 | 81 | 0.030 |
Why?
|
Practice Guidelines as Topic | 1 | 2018 | 374 | 0.030 |
Why?
|
Paired Box Transcription Factors | 1 | 2014 | 9 | 0.030 |
Why?
|
Middle Aged | 2 | 2016 | 10829 | 0.030 |
Why?
|
Forkhead Transcription Factors | 1 | 2014 | 26 | 0.030 |
Why?
|
Matrix Metalloproteinase 9 | 1 | 2014 | 31 | 0.030 |
Why?
|
Microscopy, Confocal | 1 | 2014 | 62 | 0.030 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2014 | 69 | 0.030 |
Why?
|
Epigenesis, Genetic | 1 | 2014 | 98 | 0.030 |
Why?
|
DNA-Binding Proteins | 2 | 2004 | 142 | 0.030 |
Why?
|
Chickens | 1 | 2013 | 40 | 0.030 |
Why?
|
Pressure | 1 | 2013 | 54 | 0.030 |
Why?
|
Up-Regulation | 2 | 2004 | 183 | 0.030 |
Why?
|
Receptors, Transforming Growth Factor beta | 1 | 2013 | 11 | 0.030 |
Why?
|
Paracrine Communication | 1 | 2012 | 8 | 0.030 |
Why?
|
Transforming Growth Factor beta2 | 1 | 2012 | 6 | 0.030 |
Why?
|
Chemokine CXCL12 | 1 | 2012 | 25 | 0.030 |
Why?
|
Sialyltransferases | 1 | 2012 | 1 | 0.030 |
Why?
|
DNA Replication | 1 | 2012 | 23 | 0.030 |
Why?
|
Cell Line, Transformed | 1 | 2012 | 13 | 0.030 |
Why?
|
Gene Knockdown Techniques | 1 | 2012 | 73 | 0.030 |
Why?
|
Gene Expression Regulation, Enzymologic | 1 | 2012 | 83 | 0.030 |
Why?
|
Interleukin-8 | 1 | 2011 | 23 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2011 | 5 | 0.030 |
Why?
|
Lymphography | 1 | 2011 | 4 | 0.030 |
Why?
|
Tumor Burden | 1 | 2011 | 60 | 0.030 |
Why?
|
Subcutaneous Fat | 1 | 2011 | 42 | 0.030 |
Why?
|
Proteome | 1 | 2011 | 34 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2011 | 81 | 0.030 |
Why?
|
K562 Cells | 1 | 2010 | 4 | 0.020 |
Why?
|
Lymph Nodes | 1 | 2011 | 92 | 0.020 |
Why?
|
Echocardiography | 1 | 2011 | 140 | 0.020 |
Why?
|
Receptor, Platelet-Derived Growth Factor beta | 1 | 2010 | 4 | 0.020 |
Why?
|
Drug Delivery Systems | 1 | 2011 | 92 | 0.020 |
Why?
|
Feasibility Studies | 1 | 2011 | 263 | 0.020 |
Why?
|
Binding Sites | 1 | 2010 | 125 | 0.020 |
Why?
|
Mammary Glands, Human | 1 | 2010 | 15 | 0.020 |
Why?
|
Chondrogenesis | 1 | 2010 | 18 | 0.020 |
Why?
|
Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2010 | 39 | 0.020 |
Why?
|
Protein Binding | 1 | 2010 | 199 | 0.020 |
Why?
|
Proto-Oncogene Proteins c-sis | 1 | 2010 | 9 | 0.020 |
Why?
|
Antibodies, Neutralizing | 1 | 2010 | 17 | 0.020 |
Why?
|
Injections, Intra-Arterial | 1 | 2009 | 6 | 0.020 |
Why?
|
Adenovirus E1A Proteins | 1 | 2009 | 5 | 0.020 |
Why?
|
Luminescent Agents | 1 | 2009 | 1 | 0.020 |
Why?
|
Luciferases, Firefly | 1 | 2009 | 3 | 0.020 |
Why?
|
Monitoring, Immunologic | 1 | 2009 | 2 | 0.020 |
Why?
|
Virus Replication | 1 | 2009 | 47 | 0.020 |
Why?
|
Fluorine Radioisotopes | 1 | 2009 | 21 | 0.020 |
Why?
|
Infusions, Intravenous | 1 | 2009 | 85 | 0.020 |
Why?
|
Cathelicidins | 1 | 2009 | 1 | 0.020 |
Why?
|
Chemotactic Factors | 1 | 2009 | 4 | 0.020 |
Why?
|
Neutralization Tests | 1 | 2009 | 12 | 0.020 |
Why?
|
Peritoneal Neoplasms | 1 | 2012 | 241 | 0.020 |
Why?
|
Primates | 1 | 2009 | 100 | 0.020 |
Why?
|
Kidney Transplantation | 1 | 2013 | 348 | 0.020 |
Why?
|
Immunoprecipitation | 1 | 2008 | 32 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2010 | 641 | 0.020 |
Why?
|
Rats | 1 | 2013 | 1604 | 0.020 |
Why?
|
Receptors, G-Protein-Coupled | 1 | 2009 | 89 | 0.020 |
Why?
|
Prognosis | 1 | 2012 | 1362 | 0.020 |
Why?
|
Chemotherapy, Adjuvant | 1 | 2008 | 163 | 0.020 |
Why?
|
Gene Expression Regulation | 1 | 2010 | 481 | 0.020 |
Why?
|
bcl-2 Homologous Antagonist-Killer Protein | 1 | 2006 | 4 | 0.020 |
Why?
|
Dimerization | 1 | 2006 | 24 | 0.020 |
Why?
|
bcl-2-Associated X Protein | 1 | 2006 | 14 | 0.020 |
Why?
|
Protein Conformation | 1 | 2006 | 85 | 0.020 |
Why?
|
Protein Structure, Tertiary | 1 | 2006 | 95 | 0.020 |
Why?
|
Piperazines | 1 | 2006 | 56 | 0.020 |
Why?
|
Triiodobenzoic Acids | 1 | 2006 | 8 | 0.020 |
Why?
|
Integrin alphaV | 1 | 2006 | 2 | 0.020 |
Why?
|
Bacteriophages | 1 | 2006 | 2 | 0.020 |
Why?
|
Receptors, Virus | 1 | 2006 | 15 | 0.020 |
Why?
|
Molecular Biology | 1 | 2006 | 7 | 0.020 |
Why?
|
Neoplasms, Experimental | 1 | 2006 | 27 | 0.020 |
Why?
|
Recombinant Fusion Proteins | 1 | 2006 | 97 | 0.020 |
Why?
|
RNA, Small Interfering | 1 | 2006 | 109 | 0.020 |
Why?
|
Dependovirus | 1 | 2006 | 17 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 1 | 1 | 2005 | 37 | 0.020 |
Why?
|
Mitogen-Activated Protein Kinase 3 | 1 | 2005 | 44 | 0.020 |
Why?
|
Drug Screening Assays, Antitumor | 1 | 2005 | 50 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 1218 | 0.020 |
Why?
|
Receptors, Estrogen | 1 | 2005 | 89 | 0.020 |
Why?
|
Estradiol | 1 | 2005 | 118 | 0.020 |
Why?
|
Melanoma, Experimental | 1 | 2004 | 10 | 0.020 |
Why?
|
Injections, Intravenous | 1 | 2004 | 73 | 0.020 |
Why?
|
HL-60 Cells | 1 | 2004 | 14 | 0.020 |
Why?
|
bcl-X Protein | 1 | 2004 | 6 | 0.020 |
Why?
|
Apoptosis Regulatory Proteins | 1 | 2004 | 33 | 0.020 |
Why?
|
Glycosaminoglycans | 1 | 2004 | 20 | 0.020 |
Why?
|
Cytarabine | 1 | 2004 | 52 | 0.020 |
Why?
|
Models, Genetic | 1 | 2004 | 92 | 0.020 |
Why?
|
Receptors, Retinoic Acid | 1 | 2003 | 9 | 0.020 |
Why?
|
Receptors, Leptin | 1 | 2003 | 6 | 0.020 |
Why?
|
Cell Cycle | 1 | 2004 | 69 | 0.010 |
Why?
|
Protein Isoforms | 1 | 2003 | 56 | 0.010 |
Why?
|
Tretinoin | 1 | 2003 | 34 | 0.010 |
Why?
|
Ureter | 1 | 2004 | 35 | 0.010 |
Why?
|
Trans-Activators | 1 | 2003 | 47 | 0.010 |
Why?
|
Hepatocytes | 1 | 2004 | 74 | 0.010 |
Why?
|
Leptin | 1 | 2003 | 66 | 0.010 |
Why?
|
Survival Analysis | 1 | 2004 | 440 | 0.010 |
Why?
|
Cancer Vaccines | 1 | 2003 | 21 | 0.010 |
Why?
|
Histocompatibility Antigens Class I | 1 | 2003 | 58 | 0.010 |
Why?
|
Antigens, CD | 1 | 2003 | 100 | 0.010 |
Why?
|
Idarubicin | 1 | 2002 | 7 | 0.010 |
Why?
|
Blood Cells | 1 | 2002 | 9 | 0.010 |
Why?
|
Mitoxantrone | 1 | 2002 | 17 | 0.010 |
Why?
|
Topotecan | 1 | 2002 | 15 | 0.010 |
Why?
|
Gene Expression Regulation, Leukemic | 1 | 2002 | 23 | 0.010 |
Why?
|
RNA, Neoplasm | 1 | 2002 | 20 | 0.010 |
Why?
|
Infant, Newborn | 1 | 2002 | 598 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2002 | 3717 | 0.010 |
Why?
|